Peregrine portfolio company Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome, Inc. (Nasdaq: IMNM), granting Immunome worldwide rights to a panel of monoclonal antibodies targeting an undisclosed target.
Under the agreement, Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating the antibodies. Nectin will receive an upfront payment and will be eligible for milestone payments and royalties.
The agreement enables Nectin to realize value from the licensed program while focusing its resources on its lead anti-PVR program, NTX1088, and advancing its pipeline of antibody drug conjugates (ADCs).
Official announcement: Nectin Therapeutics
